Skip to main content

Table 2 Base-case analysis results for caspofungin- versus fluconazole-initiated treatment strategies for hospitalized Ethiopian patients with IC/C

From: Cost-utility analysis of caspofungin and fluconazole for primary treatment of invasive candidiasis and candidemia in Ethiopia

 

Treatment Strategies

Incremental

 

CASPO -> L-AmB

[1]

FLU -> CASPO -> L-AmB

[2]

FLU -> L-AmB

[3]

[1] vs. [2]

[2] vs. [3]

[1] vs. [3]

Discounted at 3%

     
 

Life years

13.81

13.21

11.73

0.60

1.48

2.08

 

QALY

12.86

12.30

10.92

0.56

1.38

1.94

 

Cost (US$ 2021)

7714

3217

2781

4497

436

4933

 

ICUR (US$/QALY)

-

-

-

8030

316

2543

Undiscounted (0%)

     
 

Life years

20.69

19.67

17.18

1.02

2.49

3.51

 

QALY

19.25

18.31

15.99

0.94

2.33

3.26

 

Cost (US$ 2021)

10,748

3329

2875

7,419

454

7873

 

ICUR (US$/QALY)

-

-

-

7893

196

2415

  1. CASPO: Caspofungin; FLU: Fluconazole; L-AmB: Liposomal amphotericin B
Back to article page

BMC Health Services Research

ISSN: 1472-6963

Contact us